Alphamab Oncology’s JSKN003 Demonstrates Promising Results in Phase I HER2-Targeted Solid Tumor Study
Alphamab Oncology (HKG: 9966) presented compelling data from a Phase I clinical trial of its...
Academic conference
Sichuan Kelun-Biotech Presents Positive Results for Sacituzumab Tirumotecan at AACR 2024
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the presentation of favorable results from...
CARsgen Therapeutics’ CT041 Shows Promising Results in Advanced Solid Tumors at ASCO GI 2024
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the presentation of...
Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ASH Annual Meeting
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) provided updates on the clinical development of its...
Innovent Biologics Presents Positive Clinical Results for Efdamrofusp Alfa and IBI324 at AAO
Innovent Biologics, Inc. (HKG: 1801), a China-based biopharmaceutical company, has published the latest clinical results...
Abbisko Therapeutics to Present CSF-1R Inhibitor ABSK021 Data at CTOS Annual Meeting
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it will present data...
Ascentage Pharma’s Olverembatinib Showcases Promising Results at ASH Annual Meeting
Suzhou-based Ascentage Pharma (HKG: 6855) has presented the latest results of multiple studies regarding its...
Dizal’s Sunvozertinib Shows Promising Efficacy in Advanced NSCLC at ESMO 2023
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented compelling efficacy and safety data for its...
Shandong Luoxin’s LX-039 Demonstrates Promise in Phase I Oncology Study at ESMO
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a China-based pharmaceutical innovator, has published...
Kintor’s Proxalutamide Shows Promise in Metastatic Breast Cancer Study at ESMO
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published the latest data from a Phase Ic...
Ascentage Pharma’s Pelcitoclax Shows Promise in ESMO Study for NSCLC
Suzhou-based pharmaceutical company Ascentage Pharma (HKG: 6855) has published the latest results from a Phase...
Transcenta Holdings Unveils Updated Osemitamab Data in Advanced Gastric Cancer at ESMO
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has presented updated efficacy data from the expansion...
Alphamab Oncology Presents Promising Data for KN046 and KN026 at ESMO 2023
China-based Alphamab Oncology (HKG: 9966) has released data snapshots from clinical studies for two of...
Jacobio Pharma’s Glecirasib Combo Shows Promising Results in ESMO Congress 2023 Presentation
China-based Jacobio Pharma (HKG: 1167) has presented clinical data for its KRAS G12C inhibitor glecirasib...
LIQUIK Study Interim Results to Showcase Lucence’s Liquid Biopsy Advancements at WCLC 2023
Precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto, California,...
SAMR and Nine Ministries Tighten Regulations on Forums and Conferences in China
The State Administration for Market Regulation (SAMR) of China, in conjunction with nine other ministries,...
Ascletis Pharma’s ASC42 Showcased in Combination Therapy for Chronic Hepatitis B at EASL 2023
China-based Ascletis Pharma Inc. (HKG: 1672) announced the poster presentation of ASC42, a novel farnesoid...
Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ICML
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...
Keymed Biosciences’ CM313 Monoclonal Antibody Shows Promise in Phase I Study for Multiple Myeloma
China-based Keymed Biosciences Inc., (HKG: 2162) has announced that the latest results from a Phase...
Dizal Pharmaceutical Presents Updates on Sunvozertinib and Golidocitinib at ASCO 2023
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...